147 related articles for article (PubMed ID: 29237909)
1. Change of circulating antibodies against CD25-derived peptide antigen in hepatocellular carcinoma.
Wang J; Xu Y; Zhao H; Zhang X
J Cancer Res Ther; 2017; 13(5):813-816. PubMed ID: 29237909
[TBL] [Abstract][Full Text] [Related]
2. Detection of Circulating Antibodies to p16 Protein-Derived Peptides in Hepatocellular Carcinoma.
Xu Y; Gu L; Wang J; Wang Z; Zhang P; Zhang X
Lab Med; 2020 Nov; 51(6):574-578. PubMed ID: 32195537
[TBL] [Abstract][Full Text] [Related]
3. Study of circulating antibodies against CD25 and FOXP3 in breast cancer.
Liu T; Song YN; Shi QY; Liu Y; Bai XN; Pang D
Tumour Biol; 2014 Apr; 35(4):3779-83. PubMed ID: 24347486
[TBL] [Abstract][Full Text] [Related]
4. Further Study of Circulating Antibodies to P16, CD25 and FOXP3 in Hepatocellular Carcinoma.
Wang J; Xu Y; Wang Y; Zhang X; Zhang G
Onco Targets Ther; 2019; 12():10487-10493. PubMed ID: 31819529
[TBL] [Abstract][Full Text] [Related]
5. Alteration of circulating natural autoantibodies to CD25-derived peptide antigens and FOXP3 in non-small cell lung cancer.
Zhao H; Zhang X; Han Z; Xie W; Yang W; Wei J
Sci Rep; 2018 Jun; 8(1):9847. PubMed ID: 29959381
[TBL] [Abstract][Full Text] [Related]
6. Circulating autoantibody to CD25 may be a potential biomarker for early diagnosis of esophageal squamous cell carcinoma.
Guan S; Liu B; Zhang C; Lee KH; Sun S; Wei J
Clin Transl Oncol; 2013 Oct; 15(10):825-9. PubMed ID: 23423807
[TBL] [Abstract][Full Text] [Related]
7. Autoantibodies against p16 protein-derived peptides may be a potential biomarker for non-small cell lung cancer.
Zhang C; Ye L; Guan S; Jin S; Wang W; Sun S; Lee KH; Wei J; Liu B
Tumour Biol; 2014 Mar; 35(3):2047-51. PubMed ID: 24122232
[TBL] [Abstract][Full Text] [Related]
8. Latent transforming growth factor-beta binding protein-1 in circulating plasma as a novel biomarker for early detection of hepatocellular carcinoma.
Cao B; Yang L; Rong W; Feng L; Han N; Zhang K; Cheng S; Wu J; Xiao T; Gao Y
Int J Clin Exp Pathol; 2015; 8(12):16046-54. PubMed ID: 26884881
[TBL] [Abstract][Full Text] [Related]
9. A study of circulating anti-CD25 antibodies in non-small cell lung cancer.
Ye L; Li X; Sun S; Guan S; Wang M; Guan X; Lee KH; Wei J; Liu B
Clin Transl Oncol; 2013 Aug; 15(8):633-7. PubMed ID: 23263913
[TBL] [Abstract][Full Text] [Related]
10. Identification of anti-SF3B1 autoantibody as a diagnostic marker in patients with hepatocellular carcinoma.
Hwang HM; Heo CK; Lee HJ; Kwak SS; Lim WH; Yoo JS; Yu DY; Lim KJ; Kim JY; Cho EW
J Transl Med; 2018 Jun; 16(1):177. PubMed ID: 29954402
[TBL] [Abstract][Full Text] [Related]
11. Detection of circulating natural antibodies against CD25, MUC1, and VEGFR1 for early diagnosis of non-small cell lung cancer.
Liu S; Zhang X; Jiang Q; Liang T
FEBS Open Bio; 2020 Jul; 10(7):1288-1294. PubMed ID: 32392378
[TBL] [Abstract][Full Text] [Related]
12. Investigation of circulating antibodies to ANXA1 in breast cancer.
Huang Y; Zhang C; Chen C; Sun S; Zheng H; Wan S; Meng Q; Chen Y; Wei J
Tumour Biol; 2015 Feb; 36(2):1233-6. PubMed ID: 25344217
[TBL] [Abstract][Full Text] [Related]
13. Autoantibodies against glucose-regulated protein 78 as serological biomarkers in metastatic and recurrent hepatocellular carcinoma.
Ying X; Han SX; He CC; Zhou CY; Dong YP; Cai MJ; Sui X; Ma CX; Sun X; Zhang YY; Gou WL; Mason C; Zhu Q
Oncotarget; 2017 Apr; 8(15):24828-24839. PubMed ID: 28186997
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of plasma HSP90α levels for detection of hepatocellular carcinoma.
Wei W; Liu M; Ning S; Wei J; Zhong J; Li J; Cai Z; Zhang L
BMC Cancer; 2020 Jan; 20(1):6. PubMed ID: 31898536
[TBL] [Abstract][Full Text] [Related]
15. [Serum anti-Ku86: a potential biomarker for early detection of hepatocellular carcinoma].
Chu L; Zhang X; Wang G; Zhou W; Du Z; Liu A; Zhao H
Zhonghua Zhong Liu Za Zhi; 2014 Feb; 36(2):123-7. PubMed ID: 24796461
[TBL] [Abstract][Full Text] [Related]
16. Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis.
Jeon Y; Jang ES; Choi YS; Kim JW; Jeong SH
Clin Mol Hepatol; 2016 Sep; 22(3):359-365. PubMed ID: 27729630
[TBL] [Abstract][Full Text] [Related]
17. Six autoantibodies as potential serum biomarkers of hepatocellular carcinoma: A prospective multicenter study.
Okada R; Otsuka Y; Wakabayashi T; Shinoda M; Aoki T; Murakami M; Arizumi S; Yamamoto M; Aramaki O; Takayama T; Wakiyama S; Yanaga K; Amikura K; Kaneko H; Shimada H
Int J Cancer; 2020 Nov; 147(9):2578-2586. PubMed ID: 32574375
[TBL] [Abstract][Full Text] [Related]
18. Detection of Plasma Antibodies Against CD25-Derived Peptide Antigens in Bladder Cancer.
Du KL; Ji WT; Jiang QH; Wang Y
Clin Lab; 2023 May; 69(5):. PubMed ID: 37145070
[TBL] [Abstract][Full Text] [Related]
19. Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma.
Sun Y; Zhu S; Wu Z; Huang Y; Liu C; Tang S; Wei L
Oncotarget; 2017 Apr; 8(14):23427-23435. PubMed ID: 28178643
[TBL] [Abstract][Full Text] [Related]
20. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients.
Fu J; Xu D; Liu Z; Shi M; Zhao P; Fu B; Zhang Z; Yang H; Zhang H; Zhou C; Yao J; Jin L; Wang H; Yang Y; Fu YX; Wang FS
Gastroenterology; 2007 Jun; 132(7):2328-39. PubMed ID: 17570208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
